Immunotherapy Improves Outcomes in Triple Exposed Multiple Myeloma
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Ivan Borrello, MD, Tampa General Hospital, Tampa, Florida, discusses emerging therapies for patients with triple-exposed multiple myeloma.
Dr Borrello highlights the growing role of immunotherapy in later-line settings, noting that CAR T-cell and bispecific therapies are extending time to progression with response rates exceeding 80% and deep remissions, ultimately translating into improved progression-free and overall survival compared with the pre-immunotherapy era.
Transcript:
Hi, I'm Ivan Borrello, I am the director of myeloma transplant and cell therapy at Tampa General Hospital, and I'm here at the 2026 LL&M Winter Symposium in Jacksonville, Florida.
My presentation was on emerging therapies after triple-exposed patients. I think overall, the gist of the conversation, and of the talk, was that immunotherapy is really becoming a mainstay of treatment. We have now really lengthened the time to progression in third-, fourth-, and fifth-line therapies significantly with the integration of CAR T cells and bispecific-based therapy, with very, very high overall response rates in excess of 80% and with stringent complete remissions, as well as MRD negativity, to levels that were previously unprecedented prior to the advent of immunotherapy. What this is ultimately going to translate into is better progression-free survival and overall survival for patients, which I think is a very encouraging thing for patients and for the field itself.
Source:
Borrello I. Beyond the triple-class barrier: Emerging strategies and real-world insights in relapsed myeloma. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30 - February 1, 2026. Amelia Island, Florida.
